Skip to main content
Premium Trial:

Request an Annual Quote

Promega, ATCC Partner on Bioassays for Biologics Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promega and ATCC today announced a collaboration for cell banking and bioproduction of cells in order to create bioluminescence-based drug discovery assays for biologics.

The deal calls for ATCC to produce and authenticate cell banks and production lots of engineered and stock cell lines for use as cellular reagents as Promega creates a line of new cell-based assay systems for biologics. The initial system will be for biologics drug discovery.

The first product offering from the partnership will be an antibody-dependent cell-mediated cytotoxicity reporter assay from Promega, to be launched sometime this year. This and other reporter assays to be developed will provide reduced variability to bioassays for biologics, Promega said in a statement.

The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by biologic drug manufacturers.

Financial and other details of the deal were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.